<DOC>
	<DOCNO>NCT00526461</DOCNO>
	<brief_summary>RATIONALE : Photodynamic therapy use drug , HPPH , absorb tumor cell . The drug become active expose certain kind light . When drug active , tumor cell kill . PURPOSE : This phase I trial study side effect best dose photodynamic therapy use HPPH treat patient stage 0 non-small cell lung cancer .</brief_summary>
	<brief_title>Photodynamic Therapy Using HPPH Treating Patients With Stage 0 Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine maximally tolerate light dose ( MTID ) patient bronchogenic carcinoma situ ( CIS ) bronchogenic microinvasive carcinoma . - To identify systemic normal tissue toxicity result photodynamic therapy use HPPH patient . Secondary - To study tumor response patient . OUTLINE : Patients receive HPPH IV 1 hour day 1 . Approximately 2 day later , patient undergo photodynamic therapy ( PDT ) use laser light pass biopsy channel endoscope . Patients undergo endoscopic debridement day 5 . If viable tumor find outside initial treatment area , patient may receive another dose laser light without additional HPPH time . After completion study treatment , patient follow 4-6 week , 6 month , periodically thereafter .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Biopsy confirm carcinoma situ ( CIS ) microinvasive bronchogenic nonsmall cell lung carcinoma May squamous cell carcinoma , adenocarcinoma , large cell carcinoma histology Stage 0 ( CIS microinvasive ) disease , meet follow criterion : Lesion must radiographically occult definable conventional CT scan chest Lesion may may invisible white light bronchoscopy , definable photographable laserinduced fluorescence emission ( LIFE ) bronchoscopy Biopsy lesion must indicate evidence invasion beyond cartilage histopathology , may invasive basement membrane ( microinvasive carcinoma ) No evidence major pulmonary vessel encasement CT scan chest PATIENT CHARACTERISTICS : Karnofsky performance status ( PS ) 50100 % OR ECOG PS 02 Platelet count ≥ 100,000/mm^3 WBC ≥ 4,000/mm^3 Prothrombin time ≤ 1.5 time upper limit normal ( ULN ) Total bilirubin ≤ 3.0 mg/dL Creatinine ≤ 3.0 mg/dL Alkaline phosphatase ( hepatic ) SGOT ≤ 3 time ULN No porphyria hypersensitivity porphyrin porphyrinlike compound No severe chronic obstructive pulmonary disease , opinion investigator , would preclude multiple bronchoscopies partial central airway obstruction mucous/debris formation Patients underlie lung disease must judge ( principal investigator ) able withstand mucous debris formation site treatment No contraindication bronchoscopy Not pregnant Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : More 4 week since prior concurrent chemotherapy radiotherapy Prior therapy type ( e.g. , chemotherapy radiotherapy ) allow lung cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>stage 0 non-small cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>squamous cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
</DOC>